Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo, Sarah Cannon Ink Cancer Collaboration, DS-7300 Trial to Get Underway in FY2019
December 12, 2018
- Ribomic Hooks Up with US Research Consortium on FGF Aptamer Therapeutics
December 12, 2018
- Mitsubishi Tanabe Links Up with Chinese Biopharma to Streamline Search for Seed Compounds
December 12, 2018
- DS-8201 Yields 44.2% ORR in HER2-Low Breast Cancer: Daiichi Sankyo
December 11, 2018
- Avastin Top-Seller Drug in Japan for 4 Months Running: Encise Snapshot
December 11, 2018
- Pfizer Marks Foray into Japan Biosimilar Market with Remicade Follow-On
December 11, 2018
- Mitsubishi Tanabe Begins Study to Identify ALS Biomarkers
December 11, 2018
- Shionogi, Ube Join Hands on Respiratory Syncytial Virus Research
December 11, 2018
- Daiichi Sankyo Grabs Top Spot in Combined Approach of Sales Reps’ Visits, e-Detailing: Survey
December 11, 2018
- Roche Diagnostics Files PD-L1 Test Kit for Imfinzi in Japan
December 10, 2018
- Tecentriq Filed in Japan for 1st Line SCLC: Chugai
December 10, 2018
- RaQualia Launches New Subsidiary for Commercialization of New Projects
December 10, 2018
- Pfizer Files Rheumatrex for Psoriasis Based on Information in Public Domain
December 10, 2018
- Chugai’s Tecentriq Gets Orphan Status in SCLC, Entrectinib in NTRK-Mutated Solid Tumors
December 7, 2018
- Shionogi Set to Get Its Hands on Vast’s Nitric Oxide-Releasing Antimicrobial Agent
December 7, 2018
- Eisai/UCL’s Anti-Tau Antibody Heading into PI for Alzheimer’s Disease
December 7, 2018
- U3-1402 Racks Up 42.9% Response Rate in Breast Cancer Study: Daiichi Sankyo
December 7, 2018
- Teva Takeda Yakuhin Applies for Pediatric Use for Blopress Based on Information in Public Domain
December 7, 2018
- Fuji Yakuhin, Pfizer to Terminate Copromotion for Topiloric in January
December 7, 2018
- Pfizer to Transfer Antiepileptic Agent Gabapen to Fuji Pharma
December 7, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…